As Purdue Pharma LP and its creditors pushed the U.S. Supreme Court on Monday to bless liability releases granted to members of the Sackler family who own it, a skeptical Justice Ketanji Brown Jackson said it was the owners themselves who created the necessity in the first place by withdrawing billions of dollars from the business before its bankruptcy.

During oral arguments on the permissibility of nondebtor, third-party releases in bankruptcy, Justice Jackson took issue with Purdue’s position that the liability shield, which was granted in exchange for $6 billion in contributions from the Sacklers to the estate, was necessary to implement a settlement with opioid victims and confirm the company’s Chapter 11 plan.

Her specific concern related to the Sacklers’ offshoring of more than $10 billion of assets from Purdue in the years before it filed for Chapter 11, and then seeking a release of liability without themselves filing for bankruptcy and avoiding the need to lay their assets “on the table.”

“[My] understanding is not only are they not doing that, but most of the assets we’re talking about were originally in the company, and they actually took the assets from the company, which started the set of circumstances in which the company now doesn’t have enough money to pay the creditors,” Justice Jackson said.

Her point boiled down to the theory that the Sacklers are buying releases from Purdue with Purdue’s own money. She asked Purdue’s counsel why this situation would be allowed to occur even if the court doesn’t outright bar third-party releases.

Gregory G. Garre of Latham & Watkins LLP, representing Purdue, said nearly half the money transferred to the Sacklers in recent years went to cover tax liability, and that of the remaining 60%, the $6 billion being contributed to the plan amounts to 97% of the funds.

He also said the location and structure of trusts that hold most of the assets would present difficulties in trying to recover funds for the benefit of creditors.

“If this settlement doesn’t go forward then these victims would likely, even if they prevailed on their claims, present serious issues about being able to collect on them at the end of the day,” Garre argued.

But Justice Jackson didn’t buy that argument, saying the difficulty in collecting was a result of the Sacklers’ own actions in taking the money overseas.

“It’s not like by operation of law it’s necessary to [grant these releases],” she countered. “It is necessary to do this because the Sacklers have taken the money and are not willing to give it back unless they get this condition.”

Among the criteria necessary for non-consensual, third-party releases to be approved is a showing that they are necessary to the restructuring. Justice Amy Coney Barrett chimed in with support for Justice Jackson’s point, saying that the percentages of assets used to pay taxes and then to pay for the release contribution are important figures in the argument, but that the money still came from the company.

Purdue filed for bankruptcy in September 2019 to handle its liability for the opioid crisis arising from its sale and marketing of the powerful painkiller OxyContin. Its Chapter 11 plan was confirmed two years later and included releases for the Sacklers, which the bankruptcy court found were necessary to implement the restructuring. The Sacklers contributed $4.325 billion under the original plan. When a New York federal judge overturned the plan, finding the releases to be impermissible, the Sacklers increased their contributions to up to $6 billion.

On further appeal, the Second Circuit reversed the district court ruling, and the Office of the U.S. Trustee sought review by the high court.

Purdue is represented by Gregory G. Garre, Charles S. Dameron and Eric J. Konopka of Latham & Watkins LLP and Marshall S. Huebner, Benjamin S. Kaminetzky, Marc J. Tobak and Garrett L. Cardillo of Davis Polk & Wardwell LLP.

The official committee of unsecured creditors is represented by Mitchell P. Hurley, Arik Y. Preis, Sara L. Brauner, Pratik A. Shah, Z.W. Julius Chen and Lide E. Paterno of Akin Gump Strauss Hauer & Feld LLP.

Petitioner U.S. Trustee William K. Harrington is represented by Elizabeth B. Prelogar, Brian M. Boynton, Curtis E. Gannon, Masha G. Hansford, Michael S. Raab, Michael Shih, Sean R. Janda, Lawrence H. Fogelman, Peter Aronoff and Benjamin H. Torrance of the U.S. Department of Justice and Ramona D. Elliott, Nan Roberts Eitel, P. Matthew Sutko, Beth A. Levene and Sumi K. Sakata of the Executive Office of the U.S. Trustee.

The case is William K. Harrington v. Purdue Pharma LP et al., case number 23-124, in the Supreme Court of the United States.

Read more at: https://www.law360.com/personal-injury-medical-malpractice/articles/1773229?nl_pk=029cff45-637f-44e3-babf-75563f8e0bfd&utm_source=newsletter&utm_medium=email&utm_campaign=personal-injury-medical-malpractice&utm_content=2023-12-05&read_main=1&nlsidx=0&nlaidx=2?copied=1

The post How The Sacklers Took $10B out of Purdue Pharma and Used It to Buy Themselves Immunity from Liability for the Opioid Epidemic appeared first on The Thompson Law Firm.

“Going back to your question of when does it end,” Gdanski said to Judge Speiser, “that begs the question of when does it start? I tried to start this four, five years ago when we asked for this data.”

Read more at: https://www.law360.com/personal-injury-medical-malpractice/articles/1732558?nl_pk=029cff45-637f-44e3-babf-75563f8e0bfd&utm_source=newsletter&utm_medium=email&utm_campaign=personal-injury-medical-malpractice&utm_content=2023-10-25&read_main=1&nlsidx=0&nlaidx=4?copied=1

The post Discovery Disputes appeared first on The Thompson Law Firm.

A Washington federal jury has sided with a Johnson & Johnson-owned medical device maker in a product liability trial in Seattle, agreeing that the manufacturer was not liable for the injuries a Washington man claimed he suffered due to a defective knee replacement.

The jury delivered the verdict at about 4 p.m. Friday, after four days of testimony and roughly 50 minutes of deliberations, rejecting plaintiff Derrick C. Bosley Sr.’s claims that orthopedics maker DePuy negligently designed the Attune Knee System device that was implanted in his left knee in 2014 and later had to be removed and replaced.

Read more at: https://www.law360.com/personal-injury-medical-malpractice/articles/1733251?nl_pk=029cff45-637f-44e3-babf-75563f8e0bfd&utm_source=newsletter&utm_medium=email&utm_campaign=personal-injury-medical-malpractice&utm_content=2023-10-17&read_main=1&nlsidx=0&nlaidx=0?copied=1

The post Defective Knee Replacements appeared first on The Thompson Law Firm.

Moorman v. Ford and American Safety Equipment

Moorman was not easy to win and our courts continue to show that many difficulties continue.

The Eleventh Circuit refused Monday to rehear a panel decision affirming Ford Motor Co.’s jury win in a suit by the father of a driver who died in a 2016 car crash after he was ejected from the vehicle despite being properly buckled in.

Read more at: https://www.law360.com/personal-injury-medical-malpractice/articles/1715702?nl_pk=029cff45-637f-44e3-babf-75563f8e0bfd&utm_source=newsletter&utm_medium=email&utm_campaign=personal-injury-medical-malpractice&utm_content=2023-08-30&read_main=1&nlsidx=0&nlaidx=10?copied=1

For more of our Website information and a video explaining product liability cases, please click the link below.

Product Liability Explained.

The post Our Experience Litigating Seat Belt Defects appeared first on The Thompson Law Firm.

An Arizona appeals court on Tuesday revived a lawsuit alleging a urologist negligently prescribed an antibiotic that caused harmful side effects to a patient, saying medical expert testimony was not required because the U.S. Food and Drug Administration issued a “black box” warning about the drug.

Read more at: https://www.law360.com/personal-injury-medical-malpractice/articles/1680721?nl_pk=029cff45-637f-44e3-babf-75563f8e0bfd&utm_source=newsletter&utm_medium=email&utm_campaign=personal-injury-medical-malpractice&utm_content=2023-05-24&nlsidx=0&nlaidx=5?copied=1

The post FDA Black Box Warnings appeared first on The Thompson Law Firm.

The OR Black Box system, which was developed by  Surgical Safety Technologies (SST), consists of sensors and software that record video, audio, patient vital signs, and data from surgical devices. It provides multiple perspectives on an operation rather than just relying on team members’ memories. The system analyzes data and creates graphs, comments, timelines, videos, and audio claps for hospital personnel.

Here’s the link:

OR ‘black boxes’: How hospitals are borrowing from airplane technology

The post OR ‘black boxes’: How hospitals are borrowing from airplane technology appeared first on The Thompson Law Firm.

Shortages of critical medications continue to rise—including drugs used in hospital emergency rooms and to treat cancer, prescription medications, and even common over-the-counter treatments like children’s cold and flu medicine. The number of active drug shortages in the U.S. reached a peak of 295 at the end of 2022. However, drug shortages are not a new problem. They are caused by a number of factors, including economic drivers, insufficient supply chain visibility, and a continued U.S. overreliance on both foreign and geographically concentrated sources for medications and their raw materials. These shortages have cascading effects on patient care, causing delays in treatment, increasing the risk of medication errors, and requiring the use of less effective alternative treatments. Hospitals have also experienced increased costs, medication waste, and limited staffing capacity to address and remedy shortages.

Here is the link:

SHORT SUPPLY The Health and National Security Risks of Drug Shortages

The post Homeland Security Report on Severe Drug Shortages in the US appeared first on The Thompson Law Firm.

… although acute medical care presents myriad risks to patient safety, there is no category for devices designed to preserve that safety.

Why We Need a New Category for Safety Devices

The post Why We Need A New Category For Medical Safety Devices appeared first on The Thompson Law Firm.

FOR IMMEDIATE RELEASE Wednesday, June 5, 2019 Opioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global Resolution of Criminal and Civil Investigations

The post Insys $250M Opioid Penalty for Quality Fraud appeared first on The Thompson Law Firm.

In 2018, the state filed a complaint against J&J, alleging the company misrepresented their opioids as safer than other alternatives in their aggressive marketing campaign to prescribers and patients in New Hampshire. The state further alleged that J&J misrepresented their opioids as rarely addictive, negligently promoted the concept of pseudoaddiction, and disseminated of misleading statements regarding their opioids.

The link is here:

New Hampshire Announces J&J Opioid Settlements

The post More Opioid Settlements appeared first on The Thompson Law Firm.